ArticleJournal of psychopharmacology (Oxford, England)2017
Effect of doxazosin on stress reactivity and the ability to resist smoking.
Article in Journal of psychopharmacology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2020Trial
- Pain characteristics and nicotine deprivation as predictors of performance during a laboratory paradigm of smoking cessation.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2020Trial
- The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm.Psychopharmacology · 2020Trial
- Acute prazosin administration does not reduce stressor reactivity in healthy adults.Psychopharmacology · 2019Trial
- A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers.Human psychopharmacology · 2018Trial
- Doxazosin for the treatment of mental health disorders: A scoping review.PLOS mental health · 2025Article
- Modeling ability to resist alcohol in the human laboratory: A pilot study.Drug and alcohol dependence reports · 2022Article
- A novel human laboratory alcohol self-administration paradigm for medication screening: Modeling the ability to resist drinking and heavy drinking.Drug and alcohol dependence reports · 2022Article
- Consideration of sex and gender differences in addiction medication response.Biology of sex differences · 2022Review
- Closing the brain-heart loop: Towards more holistic models of addiction and addiction recovery.Addiction biology · 2022Review
- SUBSTANCE USE AND ADDICTION AFFECT MORE THAN THE BRAIN: THE PROMISE OF NEUROCARDIAC INTERVENTIONS.Current addiction reports · 2021Article
- A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.Addiction biology · 2020Article
- Stress Allostasis in Substance Use Disorders: Promise, Progress, and Emerging Priorities in Clinical Research.Annual review of clinical psychology · 2020Review
- The protective role of emotional intelligence in smoking relapse during a 12-month follow-up smoking cessation intervention.PloS one · 2020Article
- Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior.Journal of psychopharmacology (Oxford, England) · 2018Article
- Developing a laboratory model of smoking lapse targeting stress and brief nicotine deprivation.Experimental and clinical psychopharmacology · 2018Article
- Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.Journal of clinical psychopharmacologyArticle
- Intersection of stress and gender in association with transitions in past year DSM-5 substance use disorder diagnoses in the United States.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Preclinical findings support a role for α1-adrenergic antagonists in reducing nicotine-motivated behaviors, but these findings have yet to be translated to humans. The current study evaluated whether doxazosin would attenuate stress-precipitated smoking in the human laboratory. Using a well-validated laboratory analogue of smoking-lapse behavior, this pilot study evaluated whether doxazosin (4 and 8 mg/day) versus placebo attenuated the effect of stress (vs neutral imagery) on tobacco craving, the ability to resist smoking and subsequent ad-libitum smoking in nicotine-deprived smokers ( n=35). Cortisol, adrenocorticotropin, norepinephrine, epinephrine, and physiologic reactivity were assessed. Doxazosin (4 and 8 mg/day vs placebo) decreased cigarettes per day during the 21-day titration period. Following titration, doxazosin (4 and 8 mg/day vs placebo) decreased tobacco craving. During the laboratory session, doxazosin (8 mg/day vs placebo) further decreased tobacco craving following stress versus neutral imagery. Doxazosin increased the latency to start smoking following stress, and reduced the number of cigarettes smoked. Dosage of 8 mg/day doxazosin increased or normalized cortisol levels following stress imagery and decreased cortisol levels following neutral imagery. These preliminary findings support a role for the noradrenergic system in stress-precipitated smoking behavior, and support further development of doxazosin as a novel pharmacotherapeutic treatment strategy for smoking cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.